JAK2 and diffuse large B-cell lymphoma: Aberrant STAT3 activation has been documented in MM [61], Hodgkin's disease [62], anaplastic lymphoma kinase-positive (ALK) DLBCL [63], and activated B-cell (ABC) DLBCL, in which JAK2/STAT3 inhibitors trigger arrest and apoptosis [40].